NEXHY
Nippon Express Holdings, Inc.$36.00 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $36.00
1 year
+124.4%
from $16.04 · Oct 27
30 days
+124.4%
from $16.04
52-week range
$16.04–38.12
−6% from high · low Oct 27
Avg volume 20D
12
Oct 5 spike 116
Short interest
3
+50.0%
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 15 Short interest jumps 50.0% to 3
- E Sep 2 Trial readout: T-90d Trial Readout: NS-229 (Phase 2)
- E Sep 9 Trial readout: T-90d Trial Readout: NS-229 (Phase 2)
Signal stack
Where each data set points today.
- Short sellersBUILDING
Short interest +50.0% to 3 shares.
- TrendUPTREND
62% above its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 9, 2026 Clinical trial readout
T-90d Trial Readout: NS-229 (Phase 2)
Trial: Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granuloma
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 9, 2026
Trial readout
T-90d Trial Readout: NS-229 (Phase 2)
Trial: Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Sponsor: NS Pharma, Inc…
Sep 1, 2026
Trial readout
T-90d Trial Readout: NS-229 (Phase 2)
Trial: Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Sponsor: NS Pharma, Inc…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $680.5B |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Jul 15, 20263
shares short
+50.0%
vs prior settlement